Kayne Anderson Rudnick Investment Management
CLDI icon

Kayne Anderson Rudnick Investment Management’s Calidi Biotherapeutics CLDI Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5
Closed -$30.5K – 968
2023
Q3 		$30.5K Buy
+5
New +$81K ﹤0.01% 534

Other funds holding CLDI

CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.21B AUM 13.69% 1-Year Est. Return
SAMC
Spectrum Asset Management (California) Newport Beach, California $360M AUM 19.03% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $2.8B AUM 13.35% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
GL
Governors Lane New York $1.2B AUM 26.21% 1-Year Est. Return
RWI
Red Wave Investments Dillsburg, Pennsylvania $394M AUM 20.27% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's CLDI Position: Q4 2023 in Review

Kayne Anderson Rudnick Investment Management sold out of Calidi Biotherapeutics (CLDI) in Q4 2023, closing a stake of 5 shares — an estimated $30.5K sold.

Kayne Anderson Rudnick Investment Management first reported a position in CLDI in Q3 2023 and held it in 1 quarter. The position peaked at $30.5K in Q3 2023. 21 funds tracked by Wall St. Rank hold CLDI as of Q4 2023.

  • Kayne Anderson Rudnick Investment Management reported no remaining Calidi Biotherapeutics position as of Q4 2023 after selling out during the quarter.
  • Kayne Anderson Rudnick Investment Management sold 5 Calidi Biotherapeutics shares in Q4 2023, an estimated $30.5K.
  • Kayne Anderson Rudnick Investment Management first reported a position in Calidi Biotherapeutics in Q3 2023 and held it in 1 quarter.
  • Kayne Anderson Rudnick Investment Management's Calidi Biotherapeutics position peaked at $30.5K in Q3 2023.
  • 21 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q4 2023.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q4 2023, filed 13 Feb 2024.